We announced positive topline data from Cohort 2 of the Phase 1b study evaluating LTI-03 in patients diagnosed with IPF. Read our data here: https://bit.ly/3O722g9 ? We also held a call featuring IPF key opinion leader and study investigator, Prof. Andreas Gunther, M.D., Head of the Center for Interstitial and Rare Lung Diseases of the Justus Liebig University in Giessen, Germany. A replay is available here: https://bit.ly/4erACMV ? #IPF
Aileron Therapeutics
生物技术研究
Boston，MA 7,447 位关注者
Developing novel medicines to provide better treatment options for patients with life-threatening pulmonary conditions.
关于我们
Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website.
- 网站
-
https://aileronrx.com
Aileron Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Boston，MA
- 类型
- 上市公司
- 创立
- 2005
- 领域
- Drug Development、Stapled Peptides、Biopharmaceuticals、Chemistry、Chemoprotection、Myelopreservation、Chemotherapy和Supportive Care
地点
-
主要
获取路线
285 Summer Street
US，MA，Boston，02210
Aileron Therapeutics员工
动态
-
Today is the day! Join us at 4:30 pm ET for a discussion on the current treatment landscape for idiopathic pulmonary fibrosis, the significant unmet needs that remain, and emerging therapies, including our lead asset, LTI-03. Read the release here: https://bit.ly/3UIkjF7 ? #IPF?
-
-
Join us on February 15th at 4:30 pm ET for a discussion on the current treatment landscape for idiopathic pulmonary fibrosis, the significant unmet needs that remain and emerging therapies, including our lead asset, LTI-03. Register here: https://bit.ly/48Oi8nL ? #IPF
-
In October, we acquired Lung Therapeutics, a company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments. To learn more:?
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
prnewswire.com